These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. GC-MS profiling of Bauhinia variegata major phytoconstituents with computational identification of potential lead inhibitors of SARS-CoV-2 M More-Adate P; Lokhande KB; Swamy KV; Nagar S; Baheti A Comput Biol Med; 2022 Aug; 147():105679. PubMed ID: 35667152 [TBL] [Abstract][Full Text] [Related]
48. Computational discovery of dual potential inhibitors of SARS-CoV-2 spike/ACE2 and M Bekono BD; Onguéné PA; Simoben CV; Owono LCO; Ntie-Kang F Eur Biophys J; 2024 Aug; 53(5-6):277-298. PubMed ID: 38907013 [TBL] [Abstract][Full Text] [Related]
49. Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19. Sisakht M; Solhjoo A; Mahmoodzadeh A; Fathalipour M; Kabiri M; Sakhteman A Comput Biol Med; 2021 Sep; 136():104686. PubMed ID: 34340125 [TBL] [Abstract][Full Text] [Related]
50. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983 [TBL] [Abstract][Full Text] [Related]
51. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M Ghosh A; Chakraborty M; Chandra A; Alam MP J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023 [TBL] [Abstract][Full Text] [Related]
52. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681 [TBL] [Abstract][Full Text] [Related]
53. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease. Mandour YM; Zlotos DP; Alaraby Salem M J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680 [TBL] [Abstract][Full Text] [Related]
54. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315 [TBL] [Abstract][Full Text] [Related]
55. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
59. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. Choudhury C J Biomol Struct Dyn; 2021 Jul; 39(10):3733-3746. PubMed ID: 32452282 [TBL] [Abstract][Full Text] [Related]
60. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]